Progress in the study of Ser/Thr kinase Plk1

China Biotechnology

2007, Vol. 27

Issue (5): 142-145 DOI:

Progress in the study of Ser/Thr kinase Plk1

Download:

HTML

PDF(356KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Polo-like kinase 1(Plk1) play critical roles during multiple stages of cell cycle progression. Plk1 contain an N-terminal Ser/Thr kinase catalytic domain and a C-terminal region that contains two Polo-boxes. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy.

Key words： polo-like kinase 1 cell cycle tumor

Received: 20 December 2006 Published: 25 May 2007

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

. Progress in the study of Ser/Thr kinase Plk1. China Biotechnology, 2007, 27(5): 142-145.

URL:

https://manu60.magtech.com.cn/biotech/ OR https://manu60.magtech.com.cn/biotech/Y2007/V27/I5/142

[1]	ZHAO Meng-ze,LI Feng-zhi,WANG Peng-yin,LI Jian,XU Han-mei. Research Progress of Dual-target Blocking Therapy of PD-L1 and VEGF[J]. China Biotechnology, 2021, 41(9): 71-77.

[2]	LV Hui-zhong,ZHAO Chen-chen,ZHU Lian,XU Na. Progress of Using Exosome for Drug Targeted Delivery in Tumor Therapy[J]. China Biotechnology, 2021, 41(5): 79-86.

[3]	YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody[J]. China Biotechnology, 2021, 41(2/3): 78-88.

[4]	DENG Rui,ZENG Jia-li,LU Xue-mei. *Screening and Structure-activity Relationship Analysis of Anti-tumor Derived Peptides Based on Musca domestica* cecropin**[J]. China Biotechnology, 2021, 41(11): 14-22.

[5]	LIN Shi-xin,LIU Dong-chen,LEI Yun,XIONG Sheng,XIE Qiu-ling. Screening, Expression and Specificity Detection of Anti-TNF-α Nanobody[J]. China Biotechnology, 2020, 40(7): 15-21.

[6]	YANG Wei,SONG Fang-xiang,WANG Shuai,ZHANG Li,WANG Hong-xia,LI Yan. Preparation and Application of Janus Nanoparticles in Drug Delivery System[J]. China Biotechnology, 2020, 40(7): 70-81.

[7]	ZHANG Bao-hui,XIONG Hua-long,ZHANG Tian-ying,YUAN Quan. Research Progress on Vesicular Stomatitis Virus-based Oncolytic Virotherapy[J]. China Biotechnology, 2020, 40(6): 53-62.

[8]	TONG Mei,CHENG Yong-qing,LIU Jin-yi,XU Chen. Construction of a Strain for Promoting Production of Small Molecule Antibodies in Periplasmic Space of Escherichia coli[J]. China Biotechnology, 2020, 40(5): 48-56.

[9]	DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.

[10]	QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy[J]. China Biotechnology, 2020, 40(3): 96-103.

[11]	XIAO Xue-jun,TANG Qi,XINHUA Nabi. CAR-T Therapy Targeting Tumor Microenvironment[J]. China Biotechnology, 2020, 40(12): 67-74.

[12]	HE Xun,ZHANG Peng,ZHANG Jun-xiang. Progress in the Construction and Application of Organoids[J]. China Biotechnology, 2020, 40(12): 82-87.

[13]	ZHU Yongzhao,TAO Jin,REN Meng-meng,XIONG Ran,HE Ya-qin,ZHOU Yu,LU Zhen-hui,DU Yong,YANG Zhi-hong. Autophagy Protects Against Apoptosis of Human Placental Mesenchymal Stem Cells of Fetal Origin Induced by Tumor Necrosis Fator-α[J]. China Biotechnology, 2019, 39(9): 62-67.

[14]	LIU Yan,DAI Peng,ZHU Yun-feng. Research Progress of Exosome as Tumor Marker[J]. China Biotechnology, 2019, 39(8): 74-79.

[15]	Hai-yin LV,Teng-fei WANG,Ren-jun PEI. Progress in Aptamer Based Tumor Immunotherapy[J]. China Biotechnology, 2019, 39(6): 55-61.

Viewed

Full text

Abstract

Cited

Shared

Discussed